Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Ishida F. Aggressive NK-Cell Leukemia. Front Pediatr. 2018;6:292.
   PubMed Web of Science ®Google Scholar
• Ryder J, Wang X, Bao L, et al. Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature. Int J Hematol. 2007;85(1):18–25.
   PubMed Web of Science ®Google Scholar
• Song SY,Kim WS, Ko YH, et al. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica. 2002;87(12):1343–1345.
   PubMed Web of Science ®Google Scholar
• Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673–686.
   PubMed Web of Science ®Google Scholar
• Shimodaira S, ISHIDA F, KOBAYASHI H, et al. The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. Br J Haematol. 1995;90(3):578–584.
   PubMed Web of Science ®Google Scholar
• Tang YT, Wang D, Luo H, et al. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017;7(12):660.
   PubMedGoogle Scholar
• El Hussein S, Medeiros LJ, Khoury JD. Aggressive NK Cell Leukemia: current State of the Art. Cancers (Basel). 2020;12(10):2900.
   PubMed Web of Science ®Google Scholar
• Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012;103(6):1079–1083.
   PubMed Web of Science ®Google Scholar
• Lamy T, Loughran TP. Large Granular Lymphocyte Leukemia. Cancer Control. 1998;5(1):25–33.
   PubMedGoogle Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004;18(4):763–770.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Ishida F, Izutsu K, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021;56(2):347–356.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Kanate AS, DiGilio A, et al. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2017;23(5):853–856.
   PubMed Web of Science ®Google Scholar
• Mori N, Yamashita Y, Tsuzuki T, et al. Lymphomatous features of aggressive NK cell leukaemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology. 2000;37(4):363–371.
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510.
   PubMed Web of Science ®Google Scholar
• Hue SS, Oon ML, Wang S, et al. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology. 2020;52(1):111–127.
   PubMed Web of Science ®Google Scholar
• Li C, Tian Y, Wang J, et al. Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. Transl Res. 2014;163(6):565–577.
   PubMed Web of Science ®Google Scholar
• Poli A, Michel T, Thérésine M, et al. CD56 bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465.
   PubMed Web of Science ®Google Scholar
• Kanegane H, Yachie A, Miyawaki T, et al. EBV-NK cells interactions and lymphoproliferative disorders. Leuk Lymphoma. 1998;29(5–6):491–498.
   PubMed Web of Science ®Google Scholar
• Xu ZG, Iwatsuki K, Oyama N, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer. 2001;84(7):920–925.
   PubMed Web of Science ®Google Scholar
• Nicolae A, Ganapathi KA, Pham TH-T, et al. EBV-negative Aggressive NK-cell Leukemia/Lymphoma: clinical, Pathologic, and Genetic Features. Am J Surg Pathol. 2017;41(1):67–74.
   PubMed Web of Science ®Google Scholar
• Gao J, Behdad A, Ji P, et al. EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. Mod Pathol. 2017;30(8):1100–1115.
   PubMed Web of Science ®Google Scholar
• Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9(1):1567.
   PubMedGoogle Scholar
• Huang L, Liu D, Wang N, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018;28(2):172–186.
   PubMed Web of Science ®Google Scholar
• El Hussein S, Patel KP, Fang H, et al. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol. 2020;44(9):1235–1243.
   PubMed Web of Science ®Google Scholar
• Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood. 2011;118(12):3195–3204.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809.
   PubMed Web of Science ®Google Scholar
• Kwong Y-L, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–2442.
   PubMed Web of Science ®Google Scholar
• Lima M, Spínola A, Fonseca S, et al. Aggressive mature natural killer cell neoplasms: report on a series of 12 European patients with emphasis on flow cytometry based immunophenotype and DNA content of neoplastic natural killer cells. Leuk Lymphoma. 2015;56(1):103–112.
   PubMed Web of Science ®Google Scholar
• Jiang N-G, Jin Y-M, Niu Q, et al. Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood. Ann Hematol. 2013;92(1):89–96.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Iwasaki T, Watanabe N, et al. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood. 1993;81(5):1342–1346.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351–2356.
   PubMed Web of Science ®Google Scholar
• Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999;93(2):599–606.
   PubMed Web of Science ®Google Scholar
• Jung KS, Cho S-H, Kim SJ, et al. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol. 2016;9(1):41.
   PubMedGoogle Scholar
• Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860–868.
   PubMed Web of Science ®Google Scholar
• Zhang H, Meng Q, Xu L, et al. Adult aggressive natural killer cell leukemia. Am J Med Sci. 2013;346(1):56–63.
   PubMed Web of Science ®Google Scholar
• Ito T, Makishima H, Nakazawa H, et al. Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur J Haematol. 2008;81(2):107–111.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Song H-N, Park JS, et al. Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: a Multicenter Analysis Comparing Upfront and Salvage Transplantation. Biol Blood Marrow Transplant. 2018;24(12):2471–2478.
   PubMed Web of Science ®Google Scholar
• Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15.
   PubMedGoogle Scholar
• Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. Blood. 2020;136(24):2754–2763.
   PubMed Web of Science ®Google Scholar
• Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–1618. .
   PubMed Web of Science ®Google Scholar
• Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–2656.
   PubMed Web of Science ®Google Scholar
• Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130(2):733–747.
   PubMed Web of Science ®Google Scholar
• Slabik C, Kalbarczyk M, Danisch S, et al. CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease. Mol Ther Oncolytics. 2020;18:504–524.
   PubMed Web of Science ®Google Scholar
• Parri E, Kuusanmäki H, Bulanova D, et al. Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. Blood Adv. 2021;5(7):1862–1875.
   PubMed Web of Science ®Google Scholar
• Karube K, Tsuzuki S, Yoshida N, et al. Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate. Cancer Lett. 2013;333(1):47–55.
   PubMed Web of Science ®Google Scholar
• Ghosh SK, Perrine SP, Williams RM, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119(4):1008–1017.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571–2578.
   PubMed Web of Science ®Google Scholar
• Yan J, Li B, Lin B, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. Blood. 2016;128(7):948–958.
   PubMed Web of Science ®Google Scholar